All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 25, 2021
Details:
Pandion's lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 12, 2021
Details:
Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SYNB8802
Therapeutic Area: Gastroenterology Product Name: SYNB8802
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
SYNB8802 is a Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria. Poster titled "In silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria" will be presented at the conference.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT051
Therapeutic Area: Gastroenterology Product Name: BT051
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
Single doses of BT051 up to 3500 mg were generally safe and well tolerated in all healthy subjects exposed. Bacainn Therapeutics plans to initiate a Phase 1b clinical trial of BT051 in patients with moderate to severe active ulcerative colitis, based on the study results.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SER-301
Therapeutic Area: Gastroenterology Product Name: SER-301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis and induce clinical remission in patients suffering from active UC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SYNB8802
Therapeutic Area: Gastroenterology Product Name: SYNB8802
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
SYNB8802 is an engineered non-pathogenic strain of E. coli, using Synlogic's Synthetic Biotic platform, designed to consume oxalate in the GI tract and lower urinary oxalate levels, potentially reducing kidney damage due to Enteric Hyperoxaluria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
